CPT code 67227 represents retinal ablative therapy using cryotherapy or diathermy to destroy proliferative retinal neovascularization and associated fibrous tissue. This procedure is clinically important because untreated proliferative retinopathies, commonly seen in diabetic retinopathy, can progress to vitreous hemorrhage, tractional retinal detachment, and irreversible vision loss. Nationally, procedures coded with 67227 are relevant to ophthalmology surgical services and to payers managing complications of chronic disease.

Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise clinical context for 67227, the typical sites of service, and an outline of the procedural intent. The publication also covers payer coverage considerations and commonly used modifiers (list provided), benchmarking concepts, and how 67227 relates to management of proliferative retinopathy in outpatient surgical and hospital settings.

This summary equips clinicians, billing staff, and policy analysts with the foundational understanding of what 67227 denotes, why it matters from a clinical and utilization perspective, and which national payers commonly cover services described by this code. Data not available in the input is explicitly noted where applicable in detailed sections.